The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study
Abstract
Background: We hypothesised that a combined regimen of clozapine, a relatively weak D 2-dopaminergic antagonist, and sulpiride, a selective D 2 blocker, would demonstrate a greater antipsychotic efficacy by enhancing the D 2 blockade of clozapine. Method: Twenty-eight people with schizophrenia, previously unresponsive to typical antipsychotics and only partially responsive to current treatment with clozapine, received, double-blind, 600 mg/day sulpiride or placebo, in addition to an ongoing clozapine treatment. The clinical status was evaluated before, during, and at the end of 10 weeks of sulpiride addition using the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, and Hamilton Rating Scale for Depression. Results: The clozapine–sulpiride group exhibited substantially greater and significant improvements in positive and negative psychotic symptoms. About half of them, characterised by a younger age and lower baseline SAPS scores, had a mean reduction of 42.4 and 50.4% in their BPRS and SAPS scores, respectively. Conclusions: A subgroup of patients with chronic schizophrenia may substantially benefit from sulpiride addition to clozapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,701
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview
Kane, J. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296918 · Cited by 147
The Importance of Serotonin-Dopamine Interactions in the Action of Clozapine
Meltzer, H. Y. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296876 · Cited by 137
Substituted benzamide drugs as selective neuroleptic agents.
Jenner, P. G., & MARSDEN, C. D. (1981) · PubMed · Cited by 122
SELECTIVE INCREASE OF BRAIN DOPAMINE SYNTHESIS BY SULPIRIDE
Tagliamonte, A., Montis, M. G. D., Olianas, M. C., Vargiu, L., Corsini, G. U., & Gessa, G. L. (1975) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1975.tb03852.x · Cited by 113
Härnryd, C., Bjerkenstedt, L., Björk, K., et al. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb06856.x · Cited by 78
Cited by
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Metadata
- Authors
- Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1997-12
- Volume
- 171
- Issue
- 6
- Pages
- 569-573
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2166158209
- Cited by
- 260
- References
- 13
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1192/bjp.171.6.569
- The paper
- Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A. (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. British Journal of Psychiatry. https://doi.org/10.1192/bjp.171.6.569
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.